Precision Medicine R&D, accelerated.
Decode’s platform moves R&D programs from question to validated findings in weeks, not months. Automated multiomics analytics, proprietary patient data, and deep scientific expertise built into a structured program so pharma, diagnostics, and health tech teams get validated, commercially actionable results on their timeline.
5-18x
Faster than conventional R&D timelines
>90%
Accuracy, validated across two independent programs
10+
Years of multiomics R&D expertise
Slow analysis.
Months lost before the first useful result.
Decode removes
the bottleneck.
The R&D engine behind precision medicine.
Our platform unifies multiomic, clinical, and real-world data, runs it through a proven automated engine, and produces validated findings structured for your commercial roadmap, in weeks rather than months.
We’ve done this across autoimmune disease, oncology, and sepsis. The platform’s disease-agnostic design means it extends to new conditions, chronic or acute, without rebuilding from scratch.
How it works
01 Discovery Sprint
Define the question, map your data, agree on what success looks like before any platform work begins.
02 Platform Development
Dozens of standardized analytical steps from ingestion through results, spanning automated processing and expert-configured analysis.
03 Results For Your Next Stage
Validated findings structured for commercialization, regulatory review, investor diligence, or the next phase of your program.
what Our Partners Say
Platform in Action
Every program produces findings that inform the next. Early wins compound into deeper partnerships and new disease areas.
From zero to ranked biomarker candidates in under a month
A leading medical device company needed candidate sepsis RNA biomarkers fast. Decode identified top candidates across multiple analytical methods, characterized the underlying biology of each biomarker to build a bridge to clinical relevance, and delivered a ranked candidate panel with a defined path to analytical validation in under one month.
2x the predictive accuracy of conventional methods
A global pharma company needed to identify high-cost patients in a 2.1M-life commercial claims dataset. Decode’s ML models predicted 90% of total four-month spend for top-cost patients versus 42% with conventional methods, and correlated risk profiles against clinical and social determinant drivers to surface the factors behind rising cost.
